553 related articles for article (PubMed ID: 37545872)
41. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
Front Immunol; 2019; 10():757. PubMed ID: 31031757
[TBL] [Abstract][Full Text] [Related]
42. Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer.
Ren X; Cheng Z; He J; Yao X; Liu Y; Cai K; Li M; Hu Y; Luo Z
Nat Commun; 2023 Nov; 14(1):7021. PubMed ID: 37919262
[TBL] [Abstract][Full Text] [Related]
43. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
44. Hydroxypropyl-β-cyclodextrin inhibits the development of triple negative breast cancer by enhancing antitumor immunity.
Zhu M; Zhao Q; Zhang W; Xu H; Zhang B; Zhang S; Duan Y; Liao C; Yang X; Chen Y
Int Immunopharmacol; 2023 Dec; 125(Pt A):111168. PubMed ID: 37939513
[TBL] [Abstract][Full Text] [Related]
45. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
[TBL] [Abstract][Full Text] [Related]
46. Improving anti-PD-L1 therapy in triple negative breast cancer by polymer-enhanced immunogenic cell death and CXCR4 blockade.
Zhou M; Luo C; Zhou Z; Li L; Huang Y
J Control Release; 2021 Jun; 334():248-262. PubMed ID: 33915224
[TBL] [Abstract][Full Text] [Related]
47. Photosensitive small extracellular vesicles regulate the immune microenvironment of triple negative breast cancer.
Ding YN; Ding HY; Li H; Yang R; Huang JY; Chen H; Wang LH; Wang YJ; Hu CM; An YL; Zhang ZY; Yu WP; Tang QS; Shao GL
Acta Biomater; 2023 Sep; 167():534-550. PubMed ID: 37302734
[TBL] [Abstract][Full Text] [Related]
48. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
[TBL] [Abstract][Full Text] [Related]
49. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
[TBL] [Abstract][Full Text] [Related]
50. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
[TBL] [Abstract][Full Text] [Related]
51. Detachable Liposomes Combined Immunochemotherapy for Enhanced Triple-Negative Breast Cancer Treatment through Reprogramming of Tumor-Associated Macrophages.
Chen M; Miao Y; Qian K; Zhou X; Guo L; Qiu Y; Wang R; Gan Y; Zhang X
Nano Lett; 2021 Jul; 21(14):6031-6041. PubMed ID: 34240603
[TBL] [Abstract][Full Text] [Related]
52. Phenanthroindolizidine Alkaloids Isolated from
Reimche I; Yu H; Ariantari NP; Liu Z; Merkens K; Rotfuß S; Peter K; Jungwirth U; Bauer N; Kiefer F; Neudörfl JM; Schmalz HG; Proksch P; Teusch N
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142230
[TBL] [Abstract][Full Text] [Related]
53. Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer.
Zheng S; Zou Y; Tang Y; Yang A; Liang JY; Wu L; Tian W; Xiao W; Xie X; Yang L; Xie J; Wei W; Xie X
Oncoimmunology; 2022; 11(1):2020984. PubMed ID: 35003899
[TBL] [Abstract][Full Text] [Related]
54. Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide.
Mirando AC; Patil A; Rafie CI; Christmas BJ; Pandey NB; Stearns V; Jaffee EM; Roussos Torres ET; Popel AS
Oncoimmunology; 2020 May; 9(1):1760685. PubMed ID: 32923118
[TBL] [Abstract][Full Text] [Related]
55. Comparative colloidal stability, antitumor efficacy, and immunosuppressive effect of commercial paclitaxel nanoformulations.
Ye J; Li R; Yang Y; Dong W; Wang Y; Wang H; Sun T; Li L; Shen Q; Qin C; Xu X; Liao H; Jin Y; Xia X; Liu Y
J Nanobiotechnology; 2021 Jul; 19(1):199. PubMed ID: 34225762
[TBL] [Abstract][Full Text] [Related]
56. Ketoglutaric acid can reprogram the immunophenotype of triple-negative breast cancer after radiotherapy and improve the therapeutic effect of anti-PD-L1.
Tan H; Liu J; Huang J; Li Y; Xie Q; Dong Y; Mi Z; Ma X; Rong P
J Transl Med; 2023 Jul; 21(1):462. PubMed ID: 37438720
[TBL] [Abstract][Full Text] [Related]
57. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
58. Tumor-draining lymph nodes are survival niches that support T cell priming against lymphatic transported tumor antigen and effects of immune checkpoint blockade in TNBC.
O'Melia MJ; Manspeaker MP; Thomas SN
Cancer Immunol Immunother; 2021 Aug; 70(8):2179-2195. PubMed ID: 33459842
[TBL] [Abstract][Full Text] [Related]
59. The prognostic marker KRT81 is involved in suppressing CD8 + T cells and predicts immunotherapy response for triple-negative breast cancer.
Yan Z; Zhong Z; Shi C; Feng M; Feng X; Liu T
Cancer Biol Ther; 2024 Dec; 25(1):2355705. PubMed ID: 38778753
[TBL] [Abstract][Full Text] [Related]
60. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.
Yi M; Wu Y; Niu M; Zhu S; Zhang J; Yan Y; Zhou P; Dai Z; Wu K
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
